Spanios - About the company
Spanios is an unfunded company based in Houston (United States), founded in 2017 by Preethi Samuel and Bhuvanesh Dave. It operates as a Provider of patient-derived organoids (PDOs) to accelerate drug development for rare cancers. Spanios has not raised any funding yet. The company has 94 active competitors, including 30 funded and 2 that have exited. Its top competitors include companies like Pandorum, InSphero and Newcells Biotech.
Company Details
Provider of patient-derived organoids (PDOs) to accelerate drug development for rare cancers. The company has a proprietary method to create patient-derived 3D tumor models to generate qualitative analytics and advanced insights that provide researchers with a deeper understanding of cancer biology.
- Website
- www.spanioslab.com/
- Email ID
- *****@spanioslab.com
Key Metrics
Founded Year
2017
Location
Houston, United States
Stage
Unfunded
Investors
Ranked
19th among 94 active competitors
Employee Count
1 as on Aug 31, 2026
Similar Companies
Sign up to download Spanios' company profile
Spanios's funding and investors
Spanios has not raised any funding rounds yet. Spanios has 1 institutional investor.
View details of Spanios's funding rounds and investors
Spanios' founders and board of directors
Founder? Claim ProfileHere are the details of Spanios' key team members:
- Preethi Samuel: Co-Founder of Spanios. Contact Info: 1 email address
- Bhuvanesh Dave: Co-Founder of Spanios. Contact Info: 1 email address
- Vivek Ravi: CEO of Spanios.
View details of Spanios's Founder profiles and Board Members
Spanios' employee count trend
Spanios has 1 employees as of Aug 26. Here is Spanios's employee count trend over the years:
Uncover Spanios' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Spanios's Competitors and alternates
Top competitors of Spanios include Pandorum, InSphero and Newcells Biotech. Here is the list of Top 10 competitors of Spanios, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Developer of regenerative medicine and 3D tissues | $52.1M | 65/100 | ||
2nd |  InSphero 2009, Schlieren (Switzerland), Series D | Developer of cell based assays for drug screening | $35M | 62/100 | |
3rd | Newcells Biotech 2014, Newcastle Upon Tyne (United Kingdom), Series B | Developer of induced pluripotent stem cells derived organoid models for research application | $14.4M | 59/100 | |
4th |  Parallel Bio 2020, Cambridge (United States), Series A | Limited information available | $25.4M | 54/100 | |
5th |  OncoPrecision 2020, Cordoba (Argentina), Seed | Developer of personalized assays for oncology precision therapy | $4.2M | 51/100 | |
6th |  Nextandbio 2019, Seoul (South Korea), Series A | Provider of organoid technology to develop customized treatments for patients | $5.27M | 48/100 | |
7th | Xilis 2019, Durham (United States), Series B | Developer of drug discovery and precision therapy platform for oncology | $116M | 46/100 | |
8th | Developer of cell-based functional assays for cancer metastasis focused drug discovery and predictive diagnostics | $1.29M | 44/100 | ||
9th |  Pear Bio 2017, London (United Kingdom), Series A | Developer of microfluidic chip for cancer drug research | $14.2M | 44/100 | |
10th | BioDimension 2021, Bengaluru (India), Seed | Developer of biofabricating human tissues and organoids to make research | $983K | 44/100 | |
19th |  Spanios 2017, Houston (United States), Unfunded | Provider of patient-derived organoids (PDOs) to accelerate drug development for rare cancers | - | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Spanios's competitors? Click here to see the top ones
Spanios's Investments and acquisitions
Spanios has made no investments or acquisitions yet.
Reports related to Spanios
Here is the latest report on Spanios's sector:
News related to Spanios
Media has covered Spanios for 1 event in last 1 year, It was about partnerships.
•
Sonnet BioTherapeutics Collaborates with Spanios to Evaluate SON-1010 for Sarcoma Using Patient-Derived TumoroidsGlobeNewswire•Oct 15, 2025•Spanios, Sonnet BioTherapeutics
•
Spanios and White Lion Capital Partner to Accelerate Drug DevelopmentGlobeNewswire•Apr 26, 2025•Spanios, White Lion Capital
•
Strategic partnership between Spanios and GlioGuard to accelerate drug treatments for Glioblastoma (GBM)PR Newswire•Apr 01, 2025•Spanios, GlioGuard
•
Accelerated Biosciences and Spanios Partner to Advance Therapeutic Design Across Solid Tumor CancersPR Newswire•May 16, 2024•Accelerated Biosciences, Spanios
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Spanios
Explore our recently published companies
- Entrans - Prague based, 2003 founded, Funding Raised company
- Evolvez - New York based, 2019 founded, Unfunded company
- Kognico - New York based, 2003 founded, Unfunded company
- Happy Shark Media - New York based, 2019 founded, Unfunded company
- Spartan Institutional Research - New York based, 1996 founded, Unfunded company
- Ayoki Fabricon - Pune based, 1984 founded, Unfunded company
